Teradyne’s $300M FormFactor bet dwarfs an earlier Advantest deal

Teradyne has agreed to make a $300 million equity investment in FormFactor, pairing its automated chip testers with FormFactor’s probing and measurement technology. The companies announced the agreement after the U.S. market closed on Monday, October 12; completion remains subject to customary conditions and regulatory approvals.

The revealing comparison is in an earlier FormFactor announcement. In January 2025, the company disclosed a technology partnership and share purchase agreement with another test-equipment supplier, Advantest, worth approximately $15 million. Teradyne’s proposed investment is roughly 20 times that amount, TECHi calculates. FormFactor is attracting capital from companies that sell competing test platforms, rather than simply choosing one equipment partner.

For FormFactor stock investors, that makes Monday’s development a question about bargaining position and future products as much as financing. A larger strategic commitment could help coordinate development across the chip-testing chain. It does not establish a new sales figure, guaranteed customer demand or an immediate increase in earnings.

In a fixed after-hours observation supplied by Yahoo Finance, FORM traded at US$136.00 at 5:25:55 p.m. EDT on October 12, approximately 4.39% above its US$130.28 regular-session close that day. The provider’s delay interval was unspecified. That is a dated observation, not a live quote, and it does not prove the agreement caused the entire move.

What Teradyne and FormFactor agreed to do

The October 12 announcement combines a common-stock purchase with a technology collaboration. Its stated targets include high-performance computing, advanced packaging, high-bandwidth memory and silicon photonics. The companies describe an open, interoperable testing ecosystem.

FormFactor supplies the probing, interfaces and device-characterization side; Teradyne brings automated test platforms. The commercial logic is that hardware touching a chip and equipment measuring its response need to work together. A weak connection, poorly coordinated measurement or slow handoff can limit the usefulness of an otherwise capable tester.

The release does not disclose the purchase price per share, number of shares, resulting ownership percentage or a firm closing date. It also does not give a customer-revenue commitment. Those omissions prevent investors from calculating the precise ownership impact or treating the investment as contracted product sales.

There are two separate milestones to follow: completing the securities transaction and getting customers to use the joint technology. The first can happen without the second immediately producing meaningful operating profit.

The Advantest agreement changes how to read the news

FormFactor’s January 7, 2025 release disclosed approximately 335,000 shares at $44.78 each under its agreement with Advantest. Multiplying those figures gives $15,001,300, or about $15.0 million. The newly announced $300 million is almost exactly 20 times that disclosed purchase amount.

Two FormFactor equity agreements, very different scale

Agreement announced	Disclosed share investment	What the amount establishes
Advantest · January 7, 2025	About $15.0 million	335,000 shares × $44.78; approximate count
Teradyne · October 12, 2026	$300 million	Proposed investment; closing conditions remain

That comparison concerns dollars committed under the announced agreements. It does not mean Teradyne will own 20 times as many shares or receive 20 times the influence: prices, rights and final terms can differ. FormFactor’s 2025 announcement said the earlier issuance was not expected to materially affect its financial statements. Monday’s much larger dollar figure deserves a closer look.

The history supports a more interesting interpretation than “FormFactor finds a partner.” A supplier positioned between several testing systems may benefit when customers want equipment to work together across vendors. If FormFactor helps solve the shared connection and measurement problems, it can become useful to more than one platform.

But that advantage depends on execution. Shareholders should look for evidence that collaborating with one supplier improves FormFactor’s wider customer offering, rather than constraining it. The new announcement alone does not establish exclusivity, the end of the Advantest relationship, or a change in customers’ purchasing choices.

How large is $300 million for FormFactor?

The company’s second-quarter results filed with the SEC provide a useful scale comparison. At June 27, 2026, FormFactor reported $109.761 million in cash and cash equivalents and $235.879 million in marketable securities, a combined $345.640 million. Revenue for that quarter was $258.242 million, and research-and-development expense was $31.099 million.

The investment beside FormFactor’s reported finances

Measure	Amount	Period or status
Proposed Teradyne investment	$300.000 million	Announced October 12; not completed
Cash plus marketable securities	$345.640 million	Balance at June 27, 2026
Revenue	$258.242 million	Quarter ended June 27, 2026
Research and development expense	$31.099 million	Quarter ended June 27, 2026

TECHi’s calculation puts the proposed investment at 86.8% of the June cash-and-securities balance. It is also about 9.6 times that quarter’s R&D expense. These comparisons describe magnitude; the balance-sheet figures are historical, and the agreement does not earmark every dollar for research. They are not estimates of FormFactor’s cash today or its spending after closing.

For a shareholder, the relevant question is what additional capability that commitment can buy. More development capacity could be valuable if it shortens qualification times or opens a profitable product category. Capital can also earn a poor return if a promising design takes longer to win production orders than expected.

It would therefore be premature to add $300 million to an annual sales forecast. An equity investment and revenue from delivering products are different economic events. The investment’s eventual value depends on the terms shareholders receive and the operating results that follow, not simply on its size beside the last reported cash balance.

Why AI memory makes testing more valuable

The technical reason for collaboration is easiest to understand through high-bandwidth memory, or HBM. This memory uses multiple dies—individual pieces of silicon—stacked together. A fault discovered late can put more previously processed material and assembly work at risk than one caught before packaging.

In a June explanation of AI and HBM testing, FormFactor describes checking dies before assembly and testing how components interact after integration. This is the company’s technical account, not independent proof of the returns its products will generate. The practical aim is to avoid spending expensive packaging work on components that were already faulty.

Simple probability illustrates the issue. Suppose every component entering an assembly has a 99% chance of working and failures are independent. If the assembly requires all components to work, multiplying those probabilities gives a 92.3% chance for eight components, 88.6% for 12, and 85.1% for 16.

Illustration: small component risks can add up

Components that all must work	Calculation	Chance all work
8	0.99⁸ × 100	92.3%
12	0.99¹² × 100	88.6%
16	0.99¹⁶ × 100	85.1%

These are illustrative calculations, not measured HBM yields. Real manufacturing includes correlated defects, repair, redundancy, interconnect failures and additional screening. The example deliberately leaves those features out to show how a small component-level risk can accumulate when many components must function together.

It also explains why a testing improvement can be economically useful without increasing the number of wafers produced. Finding a bad component earlier may save downstream work. Whether the customer should pay more for that screening depends on the value of the failures avoided, the extra time required and the cost of the equipment.

The investment case consequently rests on something more specific than rising enthusiasm for AI: customers must obtain useful measurements at a cost they can justify. A more complicated chip is an opportunity for test suppliers, but complexity alone does not tell investors who captures the profit.

Silicon photonics provides a concrete precedent

The earlier Advantest collaboration supplies an example of what a more tangible product milestone looks like. In November 2024, the companies announced a silicon-photonics test cell integrating FormFactor’s Velox probe-station control with Advantest’s V93000 system. They described coordinated optical and electrical measurements for production testing.

That matters because a partnership becomes easier to assess when investors can identify the equipment, the workflow it replaces and the customer problem it addresses. A named integration is more concrete than a broad intention to cooperate, although it still does not establish a product’s revenue or profitability.

For the Teradyne agreement, comparable disclosures would help: which testing steps are being combined, what qualification work customers must complete and how the new configuration improves throughput or measurement quality. Investors do not need an invented sales target to judge progress. They need observable technical and commercial milestones.

The strongest counterargument: customers want cheaper testing

More testing is not automatically better for the customer—or more profitable for the supplier. FormFactor’s own advanced-packaging explanation discusses the trade-off between the cost of repeated tests and the value of catching failures at different stages. Testing every possible condition at every stage can become uneconomic.

This creates a tension inside the optimistic stock story. Better coordinated equipment may make testing faster and reduce unnecessary work. That can strengthen a supplier’s competitive position while also helping customers avoid buying as much capacity as they otherwise would have needed. More demand for computing does not translate mechanically into the same percentage increase in tester sales.

Nor does a strategic shareholder remove the risk of slower customer spending. A technically successful product can arrive before customers are ready to qualify it at scale, or compete with an approach that costs less. FormFactor has to turn improved capability into orders with attractive margins, rather than merely demonstrate that the equipment works.

The most persuasive evidence against that cautious view would be documented customer adoption, sustained production shipments and improving economics. Those are stronger signals than a stock-market reaction immediately after an announcement. Conversely, delayed qualifications or deteriorating margins would weaken the case even if the equity transaction closes on schedule.

What to watch before and after October 28

FormFactor has scheduled its third-quarter results and conference call for October 28, with the call at 1:25 p.m. Pacific time, or 4:25 p.m. EDT. That is the next scheduled opportunity for investors to hear management address the business; it is not a promise that every transaction detail will be available then.

The missing share price, share count and associated rights should come before any precise dilution calculation. Commercial updates should then distinguish existing business performance from opportunities attributed to the new collaboration. Closing proceeds, development spending and product revenue belong in separate parts of the analysis.

Investors following the wider AI supply chain can compare this with TSMC’s recently reported sales expansion: a larger business opportunity still has to convert into earnings. FormFactor adds a different angle because its role is measuring and connecting devices as chip designs become harder to test.

Monday’s agreement strengthens the evidence that FormFactor occupies a strategically useful place between chip manufacturers and test-platform suppliers. Its earlier Advantest pact makes that position more visible. The reason to keep watching is whether a much larger commitment from Teradyne produces products customers buy—and returns that justify the capital—once the announcement becomes a completed transaction.